External quality assurance of HER2 fluorescence in situ hybridisation testing: results of a UK NEQAS pilot scheme

BACKGROUND AND AIMS: Trastuzumab provides clinical benefit for advanced and early breast cancer patients whose tumours over‐express or have gene amplification of the HER2 oncogene. The UK National External Quality Assessment Scheme (NEQAS) for immunohistochemical testing was established to assess an...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Bartlett, John M S, Ibrahim, Merdol, Jasani, Bharat, Morgan, John M, Ellis, Ian, Kay, Elaine, Magee, Hilary, Barnett, Sarah, Miller, Keith
Format: Artigo
Langue:Inglês
Publié: BMJ Group 2007
Sujets:
Original Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC1995794/
https://ncbi.nlm.nih.gov/pubmed/16963466
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jcp.2006.040840
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires